NCT00941200

Brief Summary

Aims of Research Proposal:

  1. 1.To build a DNA bank in association with a comprehensive database of treatment outcomes and toxicities of cancer patients.
  2. 2.To carry out genotyping of potential candidate genes in relation to specific anti-cancer agents and to correlate genotype with treatment outcomes and toxicities.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
5,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2009

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2009

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

July 16, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 17, 2009

Completed
6.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

January 14, 2014

Status Verified

January 1, 2014

Enrollment Period

6.7 years

First QC Date

July 16, 2009

Last Update Submit

January 13, 2014

Conditions

Cancer

Study Arms (1)

Blood collection

Biological: Blood collection

Interventions

Blood collectionBIOLOGICAL
Blood collection

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Any individual who has been diagnosed with cancer is eligible.

You may qualify if:

  • Any cancer patient who is aged \>=18 is eligible.

You may not qualify if:

  • Cancer patients who are below age 18 will be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National University Hospital

Singapore, Singapore, 119074, Singapore

RECRUITING

Related Publications (2)

  • Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest. 1996 Aug 1;98(3):610-5. doi: 10.1172/JCI118830.

    PMID: 8698850BACKGROUND

  • Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007 Jan;101(1):113-21. doi: 10.1007/s10549-006-9428-0. Epub 2006 Nov 18.

    PMID: 17115111BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Blood sample

MeSH Terms

Conditions

Neoplasms

Interventions

Blood Specimen Collection

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Soo Chin Lee, MBBS, MRCP

    National University Hospital, Singapore

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Soo Chin Lee, MBBS, MRCP

CONTACT

65 6772 4629Soo_Chin_Lee@nuhs.edu.sg

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER

Study Record Dates

First Submitted

July 16, 2009

First Posted

July 17, 2009

Study Start

April 1, 2009

Primary Completion

December 1, 2015

Study Completion

December 1, 2015

Last Updated

January 14, 2014

Record last verified: 2014-01

Locations

SG(1)